Document Detail


High dose of erythropoietin in management of interferon/ribavirin induced anemia.
MedLine Citation:
PMID:  18265628     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEPO) to manage anemia in PEG-IFN/RBV treated patients, with the objective of maintaining the RBV dose, but currently no official guidelines exist. Actually, rHuEPO exact utilizable dose in PEG-IFN/RBV treated patients is not known. We describe the case of a patient with severe ribavirin-induced anemia.
Authors:
Claudio Ucciferri; Katia Falasca; Paola Mancino; Domenico De Tullio; Eligio Pizzigallo; Jacopo Vecchiet
Related Documents :
17683988 - Bloodletting-induced cardiomyopathy: reversible cardiac hypertrophy in severe chronic a...
2648518 - Overview of anemia associated with chronic renal disease: primary and secondary mechani...
2680358 - Hematologic manifestations of malignancy.
12902098 - Impaired oxygenation and increased hemolysis after cardiopulmonary bypass in patients w...
7859528 - Manometric characteristics of the pharynx, upper esophageal sphincter, esophagus, and l...
20976078 - Whole-body versus local dxa-scan for the diagnosis of osteoporosis in copd patients.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Hepato-gastroenterology     Volume:  54     ISSN:  0172-6390     ISO Abbreviation:  Hepatogastroenterology     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-02-12     Completed Date:  2008-03-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8007849     Medline TA:  Hepatogastroenterology     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2181-3     Citation Subset:  IM    
Affiliation:
Clinic of Infectious Diseases, Department of Medicine and Aging University "G d'Annunzio" Chieti-Pescara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alanine Transaminase / blood
Anemia / drug therapy*
Antiviral Agents / adverse effects*,  therapeutic use
Aspartate Aminotransferases / blood
Erythropoietin, Recombinant / administration & dosage*
Female
Hematocrit
Hemoglobins / analysis
Hepatitis C / drug therapy
Humans
Middle Aged
Ribavirin / adverse effects*,  therapeutic use
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Erythropoietin, Recombinant; 0/Hemoglobins; 0/epoetin beta; 36791-04-5/Ribavirin; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nestin expression in neoplastic, fetal, and adult pancreatic endocrine cells.
Next Document:  Can we do better than 'incidental' gallbladder cancer?